Yale spinout Isoplexis has raised $2.4 million of a potential $3.8 million round, according to a regulatory filing. The startup is developing an assay that helps researchers better understand immune response and how therapies impact individual patients on a cellular level.

It has a patent-pending “biochip” technology that analyzes and “fingerprints” single cells, studying their excretion of a number of proteins like cytokines, chemokines and growth factors. This, in turn, helps construct, the company says, “a highly accurate picture of how pathogens, drugs and biologics impact and interact with the immune system.”